JP2013541587A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013541587A5 JP2013541587A5 JP2013537807A JP2013537807A JP2013541587A5 JP 2013541587 A5 JP2013541587 A5 JP 2013541587A5 JP 2013537807 A JP2013537807 A JP 2013537807A JP 2013537807 A JP2013537807 A JP 2013537807A JP 2013541587 A5 JP2013541587 A5 JP 2013541587A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- day
- cancer
- days
- dosing regimen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MPUQHZXIXSTTDU-QXGSTGNESA-N sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7-pyrrolo[2,3-d]pyrimidinyl]-2-hydroxycyclopentyl]methyl ester Chemical compound C1[C@H](O)[C@H](COS(=O)(=O)N)C[C@H]1N1C2=NC=NC(N[C@@H]3C4=CC=CC=C4CC3)=C2C=C1 MPUQHZXIXSTTDU-QXGSTGNESA-N 0.000 claims description 36
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 13
- 231100000682 maximum tolerated dose Toxicity 0.000 claims description 13
- 238000001802 infusion Methods 0.000 claims description 8
- 238000001990 intravenous administration Methods 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- FIYXUOWXHWJDAM-UHFFFAOYSA-N methyl sulfamate Chemical compound COS(N)(=O)=O FIYXUOWXHWJDAM-UHFFFAOYSA-N 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41047810P | 2010-11-05 | 2010-11-05 | |
| US61/410,478 | 2010-11-05 | ||
| US201161488240P | 2011-05-20 | 2011-05-20 | |
| US61/488,240 | 2011-05-20 | ||
| PCT/US2011/059060 WO2012061551A1 (en) | 2010-11-05 | 2011-11-03 | Administration of nedd8-activating enzyme inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013541587A JP2013541587A (ja) | 2013-11-14 |
| JP2013541587A5 true JP2013541587A5 (https=) | 2014-12-18 |
Family
ID=46020229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013537807A Pending JP2013541587A (ja) | 2010-11-05 | 2011-11-03 | Ｎｅｄｄ８活性化酵素阻害剤の投与 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20120115892A1 (https=) |
| EP (1) | EP2635287A4 (https=) |
| JP (1) | JP2013541587A (https=) |
| WO (1) | WO2012061551A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013188881A1 (en) * | 2012-06-15 | 2013-12-19 | President And Fellows Of Harvard College | Compounds, compositions and methods for treating or preventing neurodegenerative disorders |
| US9200333B2 (en) | 2012-07-25 | 2015-12-01 | Indiana University Research And Technology Corporation | Methods for identifying modulators of murine double minute 2 |
| CA2923752A1 (en) * | 2013-05-14 | 2014-11-20 | Millennium Pharmaceuticals, Inc. | Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents |
| CA2946833C (en) * | 2014-06-24 | 2019-03-05 | Taiho Pharmaceutical Co., Ltd. | Pyrrolopyrimidine compounds for prevention of tumors based on nae inhibitory effect |
| TWI623316B (zh) * | 2015-12-22 | 2018-05-11 | Taiho Pharmaceutical Co Ltd | Antitumor effect enhancer derived from pyrrolopyrimidine compound |
| CN108210497B (zh) * | 2016-12-21 | 2019-12-20 | 天津大学 | 化合物mln4924在制备布尼亚病毒科白蛉病毒属病毒抑制剂的应用 |
| US20220133884A1 (en) * | 2019-02-26 | 2022-05-05 | Millennium Pharmaceuticals, Inc. | Compounds useful as adjuvants |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101450535B1 (ko) * | 2006-02-02 | 2014-10-14 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Ｅ１ 활성화 효소의 억제제 |
| WO2009042013A1 (en) * | 2007-08-02 | 2009-04-02 | Millennium Pharmaceuticals, Inc. | Process for the synthesis of e1 activating enzyme inhibitors |
| EP2200584A2 (en) * | 2007-09-17 | 2010-06-30 | Schering Corporation | Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same |
| SG175929A1 (en) * | 2009-05-14 | 2011-12-29 | Millennium Pharm Inc | Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate |
-
2011
- 2011-11-03 JP JP2013537807A patent/JP2013541587A/ja active Pending
- 2011-11-03 EP EP11838783.6A patent/EP2635287A4/en not_active Withdrawn
- 2011-11-03 WO PCT/US2011/059060 patent/WO2012061551A1/en not_active Ceased
- 2011-11-03 US US13/288,146 patent/US20120115892A1/en not_active Abandoned
-
2013
- 2013-10-08 US US14/048,854 patent/US20140249167A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013541587A5 (https=) | ||
| JP2012515217A5 (https=) | ||
| JP2015532292A5 (https=) | ||
| JP2013067645A5 (https=) | ||
| Falcone et al. | Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients | |
| FI3757126T3 (fi) | Menetelmä nivelreuman hoitamiseksi il-17-antagonistien avulla | |
| JP2013522212A5 (https=) | ||
| JP2011251975A5 (https=) | ||
| JP2016530280A5 (https=) | ||
| JP2010515709A5 (https=) | ||
| JP2013518086A5 (https=) | ||
| JP2012193216A5 (https=) | ||
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2016539156A5 (https=) | ||
| JP2013541583A5 (https=) | ||
| MX354493B (es) | Derivados de los factores de coagulacion sanguinea vii y viia, conjugados y complejos que comprenden los mismos, y uso de los mismos. | |
| Wang et al. | The bone, the joints and the Balm of Gilead | |
| CY1118158T1 (el) | Δευτεριωμενα 1-πιπεραζινο-3-φαινυλικα ινδανια για τη θεραπευτικη αντιμετωπιση της σχιζοφρενιας | |
| FI2683245T4 (fi) | Menetelmiä ja koostumuksia masennuksen hoitamiseen syklobentsapriiniä käyttämällä | |
| JP2017537927A5 (https=) | ||
| JP2010525042A5 (https=) | ||
| CN114259566B (zh) | 一种基于破坏氧化还原平衡的抗肿瘤组合物及应用 | |
| Hoag et al. | Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review | |
| JP2013540734A5 (https=) | ||
| EP4424709A3 (en) | Dosing regimen for anti-bcma agents |